The utility of delayed-enhancement magnetic resonance imaging for identifying nonischemic myocardial fibrosis in asymptomatic patients with biopsy-proven systemic sarcoidosis

Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(1):39-46.

Abstract

Background: The pathophysiology of sarcoidosis includes infiltrative inflammatory injury, as well as interstitial fibrosis formation. Delayed-enhancement (DE) magnetic resonance imaging (MRI) techniques have been shown to identify fibrotic tissue as areas of hyperenhancement. To test the hypothesis that DE-MRI can be used to identify myocardial fibrosis resulting from cardiac sarcoidosis, we assessed this method in asymptomatic patients with biopsy-proven systemic sarcoidosis.

Methods: Thirty-one patients with biopsy-confirmed systemic sarcoidosis and no known history of heart disease or sarcoid cardiac involvement underwent DE-MRI after gadolinium-chelate administration. The location and extent of DE were quantified by 2 radiologists experienced at evaluating cardiovascular MRI images.

Results: According to DE-MRI, 8 (26%) of the 31 patients had nonischemic fibrosis, as evidenced by abnormal DE patterns. Unlike characteristic ischemic injuries, most of the fibrosis was mid-myocardial, extending to the adjacent endocardium, epicardium, or both. The most frequent site of fibrosis was the basal inferoseptum, followed by the basal inferolateral wall.

Conclusions: In asymptomatic patients with systemic sarcoidosis, DE-MRI may provide a novel, noninvasive method for the early identification of myocardial fibrosis.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Biopsy*
  • Cardiomyopathies / pathology*
  • Contrast Media*
  • Early Diagnosis
  • Endocardium / pathology
  • Female
  • Fibrosis
  • Humans
  • Magnetic Resonance Imaging, Cine*
  • Male
  • Middle Aged
  • Myocardium / pathology*
  • Organometallic Compounds*
  • Pericardium / pathology
  • Predictive Value of Tests
  • Prospective Studies
  • Sarcoidosis / pathology*

Substances

  • Contrast Media
  • Organometallic Compounds
  • gadoversetamide